Trends in Cancer

Article	Citations
Revumenib: a new era in acute leukemia treatment	265
Tumor-resident microbes: the new kids on the microenvironment block	261
Platelets: tailoring metastasis treatment	238
Cancer evolution: from Darwin to the Extended Evolutionary Synthesis	236
Clinical perspective and treatment of immune-related colitis after cancer immunotherapy	209
Targeting solid tumor antigens with chimeric receptors: cancer biology meets synthetic immunology	206
Subscription & copyright page	205
FBXW10: a male-biased E3 ligase in liver cancer	190
Spliced to kill: RNA mis-splicing derived cancer neoantigens	190
Advancements in organoid models emulating metastatic niches	181
Engineering growth factor ligands and receptors for therapeutic innovation	180
Navigating life as an early career researcher	175
Leveraging circulating microbial DNA for early cancer detection	163
Onco-condensates: formation, multi-component organization, and biological functions	162
Advisory Board and Contents	154
Subscription and copyright page	154
Subscription & copyright page	142
Accessing the vasculature in cancer: revising an old hallmark	136
Engine shutdown: migrastatic strategies and prevention of metastases	133
Emerging signaling mediators in the anorexia–cachexia syndrome of cancer	121
Neural hijacking in cancer metabolism: from nutrients to organelles	113
Subscription & copyright page	112
Nonrepair functions of DNA mismatch repair proteins: new avenues for precision oncology	103
FGFR rearrangements: oncogenic drivers and therapeutic targets	102
Oncogenic competence: balancing mutations, cellular state, and microenvironment	100

Molecular insights into SMARCA2 degradation in SMARCA4-mutant lung cancers	99
cGAS–STING and the deadly CIN: how chronic inflammation represents a therapeutic vulnerability in chromosomally unstable cancers	98
GOT2 consider the tumor microenvironment	97
Advancements in combining targeted therapy and immunotherapy for colorectal cancer	93
Recent developments in myeloid immune modulation in cancer therapy	92
Gut microbiota – a double-edged sword in cancer immunotherapy	86
Targeting the Hippo pathway in cancer: kidney toxicity as a class effect of TEAD inhibitors?	81
From prediction to precision: how immunopeptidomics advances neoantigen discovery	80
The gut–liver axis: host microbiota interactions shape hepatocarcinogenesis	80
Benefits and opportunities of the transgenic Oncopig cancer model	77
Diet, nutrient supply, and tumor immune responses	74
The evolving landscape of brain metastasis: volume II	74
Crosstalk of T cells within the ovarian cancer microenvironment	74
Cell death, therapeutics, and the immune response in cancer	72
Chromatin as an old and new anticancer target	71
Advisory Board and Contents	68
Regulation of metastatic organotropism	68
Subscription & copyright page	67
Cancer immunotherapeutic challenges from autophagy-immune checkpoint reciprocal regulation	66
Organellar pH as an emerging vulnerability to exploit in cancer	64
Palmitate paves the way to lung metastasis	62
Genetic immune escape in cancer: timing and implications for treatment	62
Toward mutational epidemiology: using mutational signatures of environmental exposures to assess cancer risk	62
Planning for cancer: building accessible and high-quality survivorship care for all	62
Scaling data toward pan-cancer foundation models	60
The emerging field of oncolytic virus-based cancer immunotherapy	60
Insights on ErbB glycosylation – contributions to precision oncology	60
Clinical and translational relevance of intratumor heterogeneity	59
Transcriptional regulation of hypoxic cancer cell metabolism and artificial intelligence	58
Inflammation: the incubator of the tumor microenvironment	58
Subscription & copyright page	56
Updating cancer research with patient-focused networks	54
Advancing cancer precision surgery with the tumor coagulome	54
Advisory Board and Contents	53
Advisory Board and Contents	53
Advisory Board and Contents	53
Advisory Board and Contents	52
Prospects for understanding and exploiting the consequences of hyperactivation lethality	51
Cuproptosis in cancer: from molecular mechanisms to therapeutic intervention	51
Endogenous and imposed determinants of apoptotic vulnerabilities in cancer	50
Stress granules and hormetic adaptation of cancer	49
RHOA takes the RHOad less traveled to cancer	49
Circulating cell-free DNA-based multi-cancer early detection	49
B7-H3: a robust target for immunotherapy in prostate cancer	49
Emerging mechanisms of telomerase reactivation in cancer	48
Gastric cancer immunosuppressive microenvironment heterogeneity: implications for therapy development	46
Advisory Board and Contents	46
Molecular and clinical insights into early-onset endometrial cancer	46
Advisory Board and Contents	46
Advisory Board and Contents	46

Targeting TIM-3 to halt lung precancer progression	45
Beyond safety: suicide systems in cell-based cancer therapies	44
Subscription & copyright page	44
A macrophage-neutrophil program drives mammary carcinogenesis	43
Advisory Board and Contents	43
Leveraging space innovations for cancer breakthroughs on Earth	43
Orchestrating tumor-immune epigenetics via SERT–H3Q5ser axis	42
Branched chain amino acids and their aberrant metabolism in cancer	42
Time-of-day dependency of adoptive cell therapies	42
Neoantigen-directed therapeutics in the clinic: where are we?	42
RNA vaccines for cancer: revolutionizing immunization strategies	42
Subscription & copyright page	42
The promise of TIL therapy for glioblastoma	41
Mechanistic cancer prevention comes of age	41
Functional heterogeneity of fibroblasts in primary tumors and metastases	40
The evolving posology and administration of immune checkpoint inhibitors: subcutaneous formulations	39
Metabolism and epigenetics: drivers of tumor cell plasticity and treatment outcomes	39
CAR T cell persistence in cancer	39
Advisory Board and Contents	38
Subscription & copyright page	38
Ferroptosis vulnerability in FLT3-mutant leukemia	37
ApCAFs: spatial niches and therapeutic insights across cancers	35
Advisory Board and Contents	35
Advisory Board and Contents	35
Neural circuits in lung adenocarcinoma modulate immunosurveillance	34
Engineered bacterial therapeutics for detecting and treating CRC	34
Advisory Board and Contents	34
Space in cancer biology: its role and implications	33
Dissecting histological transformation	33
Tumor-draining lymph nodes – friend or foe during immune checkpoint therapy?	33
Dying to survive: harnessing inflammatory cell death for better immunotherapy	32
In vivo macrophage engineering as novel therapeutic strategy against liver metastasis	31
Addressing the genetic/nongenetic duality in cancer with systems biology	31
Clonal evolution and hierarchy in myeloid malignancies	31
Advisory Board and Contents	31
Targeting myeloid cells for cancer immunotherapy: Siglec-7/9/10/15 and their ligands	31
Subscription & copyright page	31
NETscape or NEThance: tailoring anti-cancer therapy	30
IL-33 and ILC2 in pancreatic cancer: good, bad or a bit of both?	30
A new enhancer for anti-PD-1/PD-L1 immunotherapy: PCSK9 inhibition	30
Next-generation cancer vaccines and emerging immunotherapy combinations	30
Immunomodulation by endothelial cells: prospects for cancer therapy	30
Lifileucel: the first cellular therapy approved for solid tumours	30
Mapping heterogeneity in the tumor microenvironment of renal cell carcinoma through single-cell omics	29
Genitourinary cancer neoadjuvant therapies: current and future approaches	29
Subscription & copyright page	29
The development of therapy related myeloid neoplasms in childhood cancer survivors	28
Using Drosophila to uncover the role of organismal physiology and the tumor microenvironment in cancer	28
Epigenetic reprogramming in pediatric gliomas: from molecular mechanisms to therapeutic implications	27
Mesothelioma: a systemic therapy clinical trials snapshot	26
Subscription & copyright page	26
IGSF3-mediated potassium dysregulation promotes neuronal hyperexcitability and glioma progression	26
How cancer cells make and respond to interferon-I	25
Subscription & copyright page	25
CRISPR tools for T cells: targeting the genome, epigenome, and transcriptome	25
Embracing diversity: macrophage complexity in cancer	25
Successfully targeting the cancer system with metronomics for medulloblastoma	25
Persisting cancer cells are different from bacterial persisters	24
Future perspectives on engineered T cells for cancer	24
Tissue architecture in tumor initiation and progression	24
Deciphering the roles of ABCB5 in normal and cancer cells	24
The extracellular matrix in cancer: from understanding to targeting	24
Towards enhancing the predictive value of the microbiota for cancer immunotherapy	23
Subscription & copyright page	23
Think zebras: challenges and opportunities for treating rare cancers	23
Self-reactive, innate-like T cells enhance cytotoxicity and immunosurveillance	23
TET2, tumor control, and CAR T cell hyperproliferation	22
Enhancing dendritic cells by inhibiting BCL2	22
Emerging and extensive clonal evolution in the pancreas	21
Extracellular vesicle lipids in cancer immunoevasion	21
Bone marrow microenvironment: roles and therapeutic implications in obesity-associated cancer	21
Circulating extracellular vesicles and tumor cells: sticky partners in metastasis	21
Poised epigenetic states dictate metastatic fitness	21
Defining obesity in the context of cancer: thinking beyond body mass index	21
Advancing human leukocyte antigen-based cancer immunotherapy: from personalized to broad-spectrum strategies for genetically heterogeneous populations	20
Hypoxia orchestrates the lymphovascular–immune ensemble in cancer	20
Small cell lung cancer profiling: an updated synthesis of subtypes, vulnerabilities, and plasticity	20
Acetylation: a new target for protein degradation in cancer	20
The clinical landscape of CAR-engineered unconventional T cells	20
Fueling the revolution: RIBOTACs manipulating RNA decay	20

Watching cancer begin: emerging tools to visualize the first steps of tumorigenesis	19
Tackling the next decade of cancer research	19
A growing entourage for heterotypic circulating tumor cell clusters	19
Interferon epsilon and ovarian cancer	19
Subscription & copyright page	19
Current landscape of CD3 bispecific antibodies in hematologic malignancies	19
The redox paradox in HGGs: ROS as drivers and destroyers	19
Dynamic immune signatures as biomarkers for irAEs	19
ALPK1 agonists ignite innate immunity in anticancer therapy	18
Advisory Board and Contents	18
Limited dsRNA editing impedes leukemia stem cells	18
Time to heal: inhibiting fibrosis prevents glioblastoma recurrence	18
Intracranial CAR-T cell delivery in glioblastoma patients	18
Regulated cell death modalities: breaking resistance of temozolomide glioblastoma therapy	18
The tumor-draining lymph node as a reservoir for systemic immune surveillance	18
Navigating the biophysical landscape: how physical cues steer the journey of bone metastatic tumor cells	18
Tissue mechanics in tumor heterogeneity and aggression	18
Mechanisms of T cell exhaustion guiding next-generation immunotherapy	18
Intratumoral immune cell manipulations as a strategy to enhance cancer vaccine efficiency	17
Targeting phagocytosis to enhance antitumor immunity	17
Wargaming cancer: a strategy for future precision oncology?	17
A biopsychosocial model to understand racial disparities in the era of cancer immunotherapy	17
Advisory Board and Contents	17
Reductive stress in cancer: coming out of the shadows	16
Lifestyle and host determinants of antitumor immunity and cancer health disparities	16
mtDNA transfer from senescent cancer cells to MDSCs promotes immunosuppression	16
Spatial promoter–enhancer hubs in cancer: organization, regulation, and function	16
Adaptive inhibition of CGAS signaling by TREX1	16
KRAS inhibitors: resistance drivers and combinatorial strategies	16
Polo-like kinases as immune modulators: a new frontier in cancer immunotherapy	15
Subscription & copyright page	15
Subscription & copyright page	15
Spatially resolving cancer: from cell states to therapy	15
Many faces, many places: delving deeper into CAF heterogeneity in NSCLC	15
Ancestry-defined molecular taxonomy of prostate cancer	15
Harnessing FLASH irradiation to improve immunotherapy of medulloblastoma	15
Advances in targeting RNA modifications for anticancer therapy	14
Myeloid cell path to malignancy: insights into liver cancer	14
The peritumor microenvironment: physics and immunity	14
Label-free optical imaging for brain cancer assessment	14
Targeting cyclin-dependent kinases in cancer: emerging therapeutics and clinical strategies	14
State-matched organoid models to fight pancreatic cancer	14
Metabolic landscape of disseminated cancer dormancy	13
Subscription & copyright page	13
Impact of tissue-agnostic approvals on management of primary brain tumors	13
Immune organoids: from tumor modeling to precision oncology	13
Subscription & copyright page	13
Into the era of mycobiome-driven cancer research	13
Advisory Board and Contents	13
Lost but not least: Y chromosome loss as a driver of cancer	13
Epigenetic control of immunoevasion in cancer stem cells	12
Disarming cancer resistance: FAK as a therapeutic target	12
Drug independence and the curability of cancer by combination chemotherapy	12
Neuro-immune interactions and immuno-oncology	12
The emerging roles of the urea cycle in tumor microenvironment and therapies	12
Immunometabolism of CD8+ T cell differentiation in cancer	12
Emerging roles of nucleotide metabolism in cancer	12
Advisory Board and Contents	12
Treatment of patients with pMMR GI cancers with tumor-infiltrating lymphocytes (TIL): a reality?	12
Leveraging immunologically based therapies to treat diffuse large B-cell lymphoma	12
Host and microbiome lipid metabolism in colorectal cancer development and therapy	12
The future of cancer research: invest now	12
γδT cells and breast cancer: wicked allies	12
Cancer fitness genes: emerging therapeutic targets for metastasis	11
Low tumor mutational burden and immunotherapy in gliomas	11
Immune cells in residual disease and recurrence	11
Trends in cancer imaging	11
Subscription and copyright page	11
Targeting cancer stem cells in multiple myeloma	11
CX3CL1: a key switch of cell death immunogenicity	11
Advisory Board and Contents	11
Generation of tumor neoantigens by RNA splicing perturbation	10
Plastic persisters: revival stem cells in colorectal cancer	10
EZHIP’s role in diffuse midline glioma: echoes of oncohistones?	10
Subscription & copyright page	10
CD4+ T cells in antitumor immunity	10
Optimizing the future: how mathematical models inform treatment schedules for cancer	10
Therapeutic targeting of regulatory T cells in cancer	10
Anxiolytics cause anxiety in pancreatic cancer	10
Small molecules targeting microRNAs: new opportunities and challenges in precision cancer therapy	10
Neuronal and tumourigenic boundaries of glioblastoma plasticity	10
Targeting vulnerabilities of aneuploid cells for cancer therapy	10
Immune mechanisms of toxicity from checkpoint inhibitors	10
The urgent need to improve childhood cancer cachexia	9
Targeting phagocytosis to enhance antitumor immunity	9
Advisory Board and Contents	9
Decoding endoplasmic reticulum stress signals in cancer cells and antitumor immunity	9
HSPC-like blasts in acute lymphoblastic leukemia: biology and therapeutic opportunities	9
A lysosomal requiem for glioblastoma cells	9
Subscription & copyright page	9
Immune vulnerabilities of mutant KRAS in pancreatic cancer	9
The future of tumor organoids in precision therapy	8
Spatial determinants of CD8+ T cell differentiation in cancer	8
Interleukin-10 in cancer immunotherapy: from bench to bedside	8
Guilt by association: EcDNA as a mobile transactivator in cancer	8